|
Process aggregate
|
|
ILX:0109383
|
2
|
FDI Lab - SciCrunch.org
|
01/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Process boundary
|
p is a process boundary =Def. p is a temporal part of a process & p has no proper temporal parts. (axiom label in BFO2 Reference: [084-001])
|
ILX:0109384
|
3
|
FDI Lab - SciCrunch.org
|
06/12/2021
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Processed image attribute
|
Attributes of images that result from the processing of the raw image data
|
ILX:0109385
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Processing Function
|
Code or description of processing functions applied to the data.
|
ILX:0109386
|
4
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Processual context
|
|
ILX:0109387
|
2
|
FDI Lab - SciCrunch.org
|
01/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Processual entity
|
An occurrent [span:Occurrent] that exists in time by occurring or happening, has temporal parts and always involves and depends on some entity.
|
ILX:0109388
|
4
|
FDI Lab - SciCrunch.org
|
06/23/2020
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Prochlorperazine
|
A phenothiazine antipsychotic used principally in the treatment of nausea; vomiting; and vertigo. It is more likely than chlorpromazine to cause extrapyramidal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612) Pharmacology: Prochlorperazine is a piperazine phenothiazine related to high-potency neuroleptics such as perphenazine. It shares many of the actions and adverse effects of the antipsychotics. Mechanism of action: Prochlorperazine blocks the D2 somatodendritic autoreceptor, resulting in the blockade of postsynaptic dopamine receptors in the mesolimbic system and an increased dopamine turnover. The antiemetic effects of prochlorperazine can be attributed to dopamine blockade in the chemoreceptor trigger zone. Prochlorperazine also blocks anticholinergic and alpha-adrenergic receptors, the blockade of alpha(1)-adrenergic receptors resulting in sedation, muscle relaxation, and hypotension. Drug type: Approved. Small Molecule. Drug category: Antiemetics. Antipsychotic Agents. Antipsychotics. Dopamine Antagonists. Phenothiazines
|
ILX:0109389
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Procyclidine
|
A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism. (PubChem) Pharmacology: Procyclidine has an atropine-like action. It's antispasmodic effects are thought to be related to the blockage of central cholinergic receptors M1, M2 and M4. It is used to treat symptomatic Parkinsonism and extrapyramidal dysfunction caused by antipsychotic agents. Mechanism of action: The mechanism of action is unknown. It is thought that Procyclidine acts by blocking central cholinergic receptors, and thus balancing cholinergic and dopaminergic activity in the basal ganglia. Many of its effects are due to its pharmacologic similarities with atropine. Drug type: Approved. Small Molecule. Drug category: Antidyskinetics. Antiparkinson Agents. Muscarinic Antagonists
|
ILX:0109390
|
4
|
FDI Lab - SciCrunch.org
|
08/24/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
troy sincomb |
|
Production service resource
|
Any resource that provides a service whose intent is to produce a physical object including a custom micro-array chip or a made-to-order antibody.
|
ILX:0109391
|
4
|
FDI Lab - SciCrunch.org
|
08/10/2023
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
Fahim Imam |
|
Profile specification
|
A specification that restricts the usage options in one or more other specifications for a particular community or application, e.g. the INSPIRE profile of ISO 19115. (CINERGI)
|
ILX:0109392
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Proflavine
|
3,6-Diaminoacridine. Topical antiseptic used mainly in wound dressings. (PubChem) Pharmacology: Proflavine is an acriflavine derivative which is a disinfectant bacteriostatic against many gram-positive bacteria. Proflavine is toxic and carcinogenic in mammals and so it is used only as a surface disinfectant or for treating superficial wounds. Mechanism of action: Proflavine acts by interchelating DNA (intercalation), thereby disrupting DNA synthesis and leading to high levels of mutation in the copied DNA strands. This prevents bacterial reproduction. Drug type: Approved. Small Molecule. Drug category: Anti-Infective Agents, Local. Anti-Infectives, local
|
ILX:0109393
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Progabide
|
Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. Progabide has been investigated for many diseases besides epilepsy, including Parkinson's disease, schizophrenia, clinical depression and anxiety disorder with varying success. Pharmacology: Progabide, a fatty acid derivative, is a GABA receptor agonist used to treat the symptoms of epilepsy. Mechanism of action: Progabide binds to both GABAA and GABAB receptors located on the terminals of primary afferent fibers. Binding to GABAA results in an increased affinity of the GABA receptor for the amino acid, an augmented flux of chloride ions across the terminal membrane, and an increase in the amount of presynaptic inhibition. Activation of the GABAB receptors retards the influx of calcium ions into the terminals, thereby reducing the evoked release of excitatory amino acids and possibly other transmitters. Drug type: Approved. Small Molecule. Drug category: Anticonvulsants. Antidepressants. Antidepressive Agents. Antidyskinetics. Antiparkinson Agents. GABA Agonists
|
ILX:0109394
|
4
|
FDI Lab - SciCrunch.org
|
08/24/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
troy sincomb |
|
Progenetic growth
|
A paedomorphic growth quality which is due to an earlier offset.
|
ILX:0109395
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Progeny
|
|
ILX:0109396
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Progesterone
|
The major progestational steroid that is secreted primarily by the corpus luteum and the placenta. Progesterone acts on the uterus, the mammary glands and the brain. It is required in embryo implantation; pregnancy maintenance, and the development of mammary tissue for milk production. Progesterone, converted from pregnenolone, also serves as an intermediate in the biosynthesis of gonadal steroid hormones and adrenal corticosteroids. (PubChem) Pharmacology: Progesterone is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Progesterone tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries. Mechanism of action: Binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Progesterone will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. Drug type: Approved. Small Molecule. Drug category: Contraceptives. Progestins
|
ILX:0109397
|
4
|
FDI Lab - SciCrunch.org
|
08/24/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
troy sincomb |
|
Programming language
|
A language in which source code is written, intended to executed/run by a software interpreter. Programming languages are ways to write instructions that specify what to do, and sometimes, how to do it (from Ontology of Biomedical Investigations)
|
ILX:0109398
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Progressive
|
Increasing over time.
|
ILX:0109399
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Progressive Bulbar Palsy
|
A motor neuron disease marked by progressive weakness of the muscles innervated by cranial nerves of the lower brain stem. Clinical manifestations include dysarthria, dysphagia, facial weakness, tongue weakness, and fasciculations of the tongue and facial muscles. The adult form of the disease is marked initially by bulbar weakness which progresses to involve motor neurons throughout the neuroaxis. Eventually this condition may become indistinguishable from AMYOTROPHIC LATERAL SCLEROSIS. Fazio-Londe syndrome is an inherited form of this illness which occurs in children and young adults (MeSH).
|
ILX:0109400
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Progressive Multifocal Leukoencephalopathy
|
An opportunistic viral infection of the central nervous system associated with conditions that impair cell-mediated immunity (e.g., ACQUIRED IMMUNODEFICIENCY SYNDROME and other IMMUNOLOGIC DEFICIENCY SYNDROMES; HEMATOLOGIC NEOPLASMS; IMMUNOSUPPRESSION; and COLLAGEN DISEASES). The causative organism is JC Polyomavirus ( JC VIRUS) which primarily affects oligodendrocytes, resulting in multiple areas of demyelination. Clinical manifestations include DEMENTIA; ATAXIA; visual disturbances; and other focal neurologic deficits, generally progressing to a vegetative state within 6 months (MeSH).
|
ILX:0109401
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |
|
Progressive Myoclonic Epilepsy
|
A heterogeneous group of primarily familial disorders characterized by myoclonic seizures, tonic-clonic seizures, ataxia, progressive intellectual deterioration, and neuronal degeneration. These include LAFORA DISEASE; MERRF SYNDROME; NEURONAL CEROID-LIPOFUSCINOSIS; sialidosis (see MUCOLIPIDOSES), and UNVERRICHT-LUNDBORG SYNDROME (MeSH).
|
ILX:0109402
|
3
|
FDI Lab - SciCrunch.org
|
06/18/2018
|
FDI Lab - SciCrunch.org |
term |
12/09/2016 |
0 |
NeuroLex |
NeuroLex |